Previous 10 | Next 10 |
Iovance Biotherapeutics (NASDAQ: IOVA ) perks up 4% premarket on light volume in reaction to positive developments on the regulatory pathway for Fast Track- and Breakthrough Therapy-tagged LN-145. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on ...
FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer SAN CARLOS, Calif., July 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company devel...
Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...
I got interested in Iovance Biotherapeutics ( IOVA ) after attending the management presentation at the Jefferies annual immuno-oncology day in Boston a couple of months back. The management presented interesting preliminary data from its tumor infiltrating lymphocytes, TILs in refractory adva...
Iovance Biotherapeutics ( IOVA ) had made a very large impact at ASCO 2019 and it was one of the clear winners for the medical conference. That's because it reported positive results from two of its studies. The positive results were made possible through the use of the biotech's Tumor infil...
SAN CARLOS, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Athena Countouriotis, M....
Genocea Biosciences ( GNCA ) presented some outstanding immunogenicity data at the American Society for Clinical Oncology ((ASCO)) 2019 medical meeting. It highlighted initial data from its phase 1/2a study using its neoantigen vaccine GEN-009. While this was just immunogenicity data, it was...
Risk comes from not knowing what you're doing. - Warren Buffett In researching a lead for Integrated BioSci Investing members, I uncovered an interesting vaccine innovator known as Genocea Biosciences ( GNCA ). Due to the company's robust data presented at the 2019 Annual Meeting of the ...
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...
Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biote...
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients wit...
2024-04-16 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...